Novavax reported $2.62B in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Adma Biologics ADMA:US $ 296.93M 11.1M
Agenus AGEN:US $ 456.17M 14.87M
AstraZeneca AZN:LN 7932612.74M 297425.43M
Astrazeneca AZN:US $ 96579M 3694M
Biocryst Pharmaceuticals BCRX:US $ 510.54M 17.18M
Dynavax Technologies DVAX:US $ 1023M 14.02M
Genocea Biosciences GNCA:US $ 38.79M 17.18M
Geron GERN:US $ 238.16M 39.74M
GlaxoSmithKline GSK:LN 8904500M 64400M
Mannkind MNKD:US $ 285.8M 22.52M
Minerva Neurosciences NERV:US $ 64.96M 5.66M
Moderna Inc MRNA:US 26.04B 1.57B
Novartis NVS:US $ 122910M 2308M
Novavax NVAX:US $ 2622.99M 211.88M
Pain Therapeutics PTIE:US $ 227.38M 16.81M
Peregrine Pharmaceuticals PPHM:US $ 451.22M 21.38M
Sarepta Therapeutics SRPT:US $ 2996.85M 59.3M
Tg Therapeutics TGTX:US $ 251.67M 51.36M